FIDIA SPA (FDA.MI) Fundamental Analysis & Valuation

BIT:FDA • IT0005654683

Current stock price

0.009 EUR
0 (0%)
Last:

This FDA.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. FDA.MI Profitability Analysis

1.1 Basic Checks

  • In the past year FDA has reported negative net income.
  • In the past year FDA had a positive cash flow from operations.
  • In the past 5 years FDA reported 4 times negative net income.
  • In multiple years FDA reported negative operating cash flow during the last 5 years.
FDA.MI Yearly Net Income VS EBIT VS OCF VS FCFFDA.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

  • FDA has a Return On Assets of -8.49%. This is amonst the worse of the industry: FDA underperforms 85.05% of its industry peers.
  • FDA has a Return On Equity of -53.14%. This is amonst the worse of the industry: FDA underperforms 88.78% of its industry peers.
Industry RankSector Rank
ROA -8.49%
ROE -53.14%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FDA.MI Yearly ROA, ROE, ROICFDA.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

  • Looking at the Gross Margin, with a value of 69.64%, FDA belongs to the top of the industry, outperforming 93.46% of the companies in the same industry.
  • In the last couple of years the Gross Margin of FDA has grown nicely.
  • The Profit Margin and Operating Margin are not available for FDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.42%
GM growth 5Y4.76%
FDA.MI Yearly Profit, Operating, Gross MarginsFDA.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. FDA.MI Health Analysis

2.1 Basic Checks

  • FDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for FDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FDA.MI Yearly Shares OutstandingFDA.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20K 40K 60K
FDA.MI Yearly Total Debt VS Total AssetsFDA.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

  • FDA has an Altman-Z score of 0.04. This is a bad value and indicates that FDA is not financially healthy and even has some risk of bankruptcy.
  • FDA's Altman-Z score of 0.04 is on the low side compared to the rest of the industry. FDA is outperformed by 83.18% of its industry peers.
  • The Debt to FCF ratio of FDA is 6.13, which is on the high side as it means it would take FDA, 6.13 years of fcf income to pay off all of its debts.
  • With a Debt to FCF ratio value of 6.13, FDA perfoms like the industry average, outperforming 48.60% of the companies in the same industry.
  • FDA has a Debt/Equity ratio of 1.41. This is a high value indicating a heavy dependency on external financing.
  • FDA has a Debt to Equity ratio of 1.41. This is amonst the worse of the industry: FDA underperforms 82.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.41
Debt/FCF 6.13
Altman-Z 0.04
ROIC/WACCN/A
WACC8.03%
FDA.MI Yearly LT Debt VS Equity VS FCFFDA.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M 15M

2.3 Liquidity

  • A Current Ratio of 1.06 indicates that FDA should not have too much problems paying its short term obligations.
  • FDA has a worse Current ratio (1.06) than 80.37% of its industry peers.
  • FDA has a Quick Ratio of 1.06. This is a bad value and indicates that FDA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • FDA has a Quick ratio of 0.46. This is amonst the worse of the industry: FDA underperforms 92.52% of its industry peers.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 0.46
FDA.MI Yearly Current Assets VS Current LiabilitesFDA.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. FDA.MI Growth Analysis

3.1 Past

  • FDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.56%, which is quite impressive.
  • Looking at the last year, FDA shows a very negative growth in Revenue. The Revenue has decreased by -27.40% in the last year.
  • The Revenue for FDA have been decreasing by -17.51% on average. This is quite bad
EPS 1Y (TTM)70.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.95%
Revenue 1Y (TTM)-27.4%
Revenue growth 3Y-9.81%
Revenue growth 5Y-17.51%
Sales Q2Q%38.18%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FDA.MI Yearly Revenue VS EstimatesFDA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
FDA.MI Yearly EPS VS EstimatesFDA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 0 50 -50

More info and screens

Find the best growth stocksShow best growing peers

2

4. FDA.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FDA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FDA.MI Price Earnings VS Forward Price EarningsFDA.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, FDA is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 0.54
EV/EBITDA N/A
FDA.MI Per share dataFDA.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FDA.MI Dividend Analysis

5.1 Amount

  • No dividends for FDA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FDA.MI Fundamentals: All Metrics, Ratios and Statistics

FIDIA SPA

BIT:FDA (4/24/2026, 3:50:05 PM)

0.009

0 (0%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners4.2%
Ins Owner ChangeN/A
Market Cap598.86K
Revenue(TTM)21.08M
Net Income(TTM)-2.19M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF 0.54
P/OCF 0.47
P/B 0.15
P/tB 0.17
EV/EBITDA N/A
EPS(TTM)-6.13
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.02
FCFY186.02%
OCF(TTM)0.02
OCFY213.07%
SpS0.32
BVpS0.06
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -8.49%
ROE -53.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.64%
FCFM 5.28%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.42%
GM growth 5Y4.76%
F-Score5
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 1.41
Debt/FCF 6.13
Debt/EBITDA N/A
Cap/Depr 12.72%
Cap/Sales 0.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.06
Quick Ratio 0.46
Altman-Z 0.04
F-Score5
WACC8.03%
ROIC/WACCN/A
Cap/Depr(3y)19.7%
Cap/Depr(5y)16.39%
Cap/Sales(3y)1.17%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.95%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-27.4%
Revenue growth 3Y-9.81%
Revenue growth 5Y-17.51%
Sales Q2Q%38.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-112.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.73%
OCF growth 3YN/A
OCF growth 5YN/A

FIDIA SPA / FDA.MI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of FIDIA SPA (FDA.MI) stock?

ChartMill assigns a fundamental rating of 1 / 10 to FDA.MI.


What is the valuation status for FDA stock?

ChartMill assigns a valuation rating of 2 / 10 to FIDIA SPA (FDA.MI). This can be considered as Overvalued.


Can you provide the profitability details for FIDIA SPA?

FIDIA SPA (FDA.MI) has a profitability rating of 2 / 10.


Is the dividend of FIDIA SPA sustainable?

The dividend rating of FIDIA SPA (FDA.MI) is 0 / 10 and the dividend payout ratio is 0%.